# Lonza expands ADC facility in Visp, Switzerland with two new suites

Lonza is adding two new conjugation suites to its antibody-drug conjugate (ADC) facility in Visp, Switzerland, with new capacity expected online by Q3 2021.

- Type: Expansion
- Announced: 2019-07-25
- Where: Visp, Switzerland
- Starts operating: Q3 2021
- Status: under construction
- Capacity: two additional suites
- Products: antibody-drug conjugates (ADCs)
- Sectors: [Medical Devices](https://endata.com/sectors/medical-devices.md)

## Companies

- [Lonza Group AG](https://endata.com/companies/20735.md)

## Sources

- [bioprocessintl.com](https://www.bioprocessintl.com/facilities-capacity/lonza-building-out-capacity-to-prep-for-adc-boom), 2019-07-25: "We are building two additional floors onto the existing building, adding two suites to the existing five."

---
Data from Endata (https://endata.com/). Announcements are summarized from public sources and may be incomplete; check the linked originals.